Cancer research, Anaplastic lymphoma kinase, Lung cancer, Crizotinib and Cancer are his primary areas of study. His biological study spans a wide range of topics, including Receptor tyrosine kinase, MSH6, Drug resistance and Gefitinib. His Anaplastic lymphoma kinase research includes themes of Anaplastic large-cell lymphoma and ROS1.
To a larger extent, A. John Iafrate studies Pathology with the aim of understanding Lung cancer. His Pathology research incorporates themes from Circulating tumor cell and Adenocarcinoma. The study of Oncology and Internal medicine are components of his Crizotinib research.
His primary areas of investigation include Cancer research, Internal medicine, Oncology, Pathology and Cancer. His Cancer research research is multidisciplinary, relying on both Mutation, KRAS, Anaplastic lymphoma kinase and Immunology. His research integrates issues of Crizotinib and ROS1 in his study of Anaplastic lymphoma kinase.
His Internal medicine research integrates issues from Gastroenterology and Bioinformatics. The study incorporates disciplines such as Genotyping, Targeted therapy, Clinical trial and Metastasis in addition to Oncology. As a part of the same scientific family, A. John Iafrate mostly works in the field of Pathology, focusing on Adenocarcinoma and, on occasion, Lung and Gene.
The scientist’s investigation covers issues in Internal medicine, Antibody, Oncology, Severe acute respiratory syndrome coronavirus 2 and Serology. His research links Genotyping with Internal medicine. The Antibody study combines topics in areas such as Immune system and Virology.
His Oncology study combines topics from a wide range of disciplines, such as Molecular analysis, Treatment options, Clinical trial and Cancer. He combines subjects such as Cancer research and Somatic cell with his study of Human brain. A. John Iafrate carries out multidisciplinary research, doing studies in Cancer research and PDGFRA.
His main research concerns Antibody, Severe acute respiratory syndrome coronavirus 2, Immunology, Immune system and Serology. His study ties his expertise on Internal medicine together with the subject of Antibody. His work on Neutralizing antibody, Seroconversion and Titer is typically connected to Persistence and Isotype as part of general Immunology study, connecting several disciplines of science.
His Immune system study combines topics in areas such as Potency, Seroprevalence, Neutralization and Cohort. His Serology research incorporates elements of Biomarker, Positive test, Retrospective cohort study and Polymerase chain reaction. A. John Iafrate has researched Humoral immunity in several fields, including Proinflammatory cytokine, Immunoglobulin G and Vaccination, Virology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw.
The New England Journal of Medicine (2010)
Detection of large-scale variation in the human genome.
A John Iafrate;Lars Feuk;Miguel N Rivera;Miguel N Rivera;Marc L Listewnik.
Nature Genetics (2004)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy.
Science Translational Medicine (2011)
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy.
Journal of Clinical Oncology (2009)
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus.
The New England Journal of Medicine (2008)
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge.
The New England Journal of Medicine (2014)
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Shengdar Q Tsai;Zongli Zheng;Nhu T Nguyen;Matthew Liebers.
Nature Biotechnology (2015)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama.
Journal of Clinical Oncology (2012)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate.
Lancet Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: